Trending...
- Yoga Retreats, Ecstatic Dance & Spiritual App launched
- 13 Full Moons of Black Dandelion Convergent Voice™ An Integration of Literacy & Wellness Symposium
- Notice: Hrm Queen Laurence I Assumes Crown Control & $317q Fund. 3bn Unopoly Shares Settled. Requisition Of Buckingham Palace & Windsor Castle Final
CHENGDU, China, April 24, 2025 ~ Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) has announced that it will be showcasing the results of six clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3. These studies, led by Kelun, include data from their TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031).
The abstracts for these studies will be published on ASCO's official website on May 22, 2025, local time. The selected studies for ASCO 2025 are focused on various types of cancer and aim to present promising treatment options for patients.
One of the studies, titled "Sacituzumab tirumotecan (sac-TMT) in patients with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study," will be presented as an oral presentation on June 1st. This study focuses on the use of sac-TMT as a potential treatment option for patients with advanced NSCLC.
More on illi News
Another study, titled "Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study," will also be presented as an oral presentation on May 31st. This study looks at the effectiveness of tagitanlimab in combination with other treatments for patients with recurrent or metastatic nasopharyngeal carcinoma.
The Phase II OptiTROP-Breast05 study will also be presented as a rapid oral presentation on May 30th. This study focuses on the use of sac-TMT as a first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC).
In addition to these presentations, there will also be a poster presentation on May 31st for the study titled "Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study." This study looks at the potential of combining sac-TMT and tagitanlimab as a first-line treatment option for patients with advanced NSCLC.
More on illi News
The remaining two studies, "Sacituzumab Tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study" and "Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer," will both be presented as poster presentations on May 31st and June 2nd respectively.
These studies demonstrate Kelun's commitment to developing innovative treatments for various types of cancer. The results presented at ASCO 2025 have the potential to significantly impact the lives of patients and improve their outcomes. The company looks forward to sharing their findings with the medical community at this prestigious event.
The abstracts for these studies will be published on ASCO's official website on May 22, 2025, local time. The selected studies for ASCO 2025 are focused on various types of cancer and aim to present promising treatment options for patients.
One of the studies, titled "Sacituzumab tirumotecan (sac-TMT) in patients with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study," will be presented as an oral presentation on June 1st. This study focuses on the use of sac-TMT as a potential treatment option for patients with advanced NSCLC.
More on illi News
- Naperville and Aurora Joint Release: North Aurora Road Closure between Pennsbury Lane & Frontenac Road Starts March 31
- American Properties Realty, Inc. Leadership Attends NAHB International Builders' Show in Florida
- Mayor Brandon Johnson Announces 2nd Annual Chicago River Swim Following Historic First Year, Establishing New Civic Tradition
- $317M Revenue and a Clear Path to $1B: $IQST is Positioned for a Major Profitability Inflection
- Jones Software Corp Expands AI Skilling Through Microsoft Commercial Marketplace with Global Deliver
Another study, titled "Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study," will also be presented as an oral presentation on May 31st. This study looks at the effectiveness of tagitanlimab in combination with other treatments for patients with recurrent or metastatic nasopharyngeal carcinoma.
The Phase II OptiTROP-Breast05 study will also be presented as a rapid oral presentation on May 30th. This study focuses on the use of sac-TMT as a first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC).
In addition to these presentations, there will also be a poster presentation on May 31st for the study titled "Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study." This study looks at the potential of combining sac-TMT and tagitanlimab as a first-line treatment option for patients with advanced NSCLC.
More on illi News
- ASI Hosts 2026 Executive Business Summit for Global Partner Community
- Pastor Saeed Abedini Releases THE TRUTH – Volume 1, A Deeply Personal Story of Faith, Struggle, and Redemption
- New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
- Scotch Whisky Market Dislocation Creates Compelling Entry Opportunity for Long-Term Investors
- Peccioli Becomes New Orleans: In July 2026, the magic of jazz comes to Tuscany
The remaining two studies, "Sacituzumab Tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study" and "Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer," will both be presented as poster presentations on May 31st and June 2nd respectively.
These studies demonstrate Kelun's commitment to developing innovative treatments for various types of cancer. The results presented at ASCO 2025 have the potential to significantly impact the lives of patients and improve their outcomes. The company looks forward to sharing their findings with the medical community at this prestigious event.
Filed Under: Business
0 Comments
Latest on illi News
- CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs
- NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
- Revenue Optics Launches Talent Infrastructure Platform for SaaS Revenue Hiring and Appoints Sabz Kaur to Lead Growth
- Building a Multi-Domain Autonomous Systems Platform at the Intersection of AI, Defense and Infrastructure: VisionWave Holdings (N A S D A Q: VWAV)
- Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
- Author Ken Mora to Celebrate New Caravaggio Book Debut with Special Event at Palazzo Venezia Naples
- The Friendly Music Community Unveils The Friendly Listening Room with Premier Performance by Acclai
- Matthew Sisneros Releases Raw and Unfiltered Memoir: The Devil Lost Another One — A Powerful Story of Crime, Consequence, and Redemption
- From Life to Light: Jess L. Martinez Shares a Soulful Poetry Collection That Explores What It Means to Be Human
- Lawsuit Filed Against Boeing Over Defective Seat Switch on Boeing 787
- New Portable Toilet Drain Adapter Eliminates Manual Waste Tank Emptying
- Quadcode Acquires Significant Stake in Game 7, LLC - The Parent Company for FPFX Tech and PropAccount.com
- Night Shade Introduces Smart Privacy Protection for Modern Devices
- Innovative Ear Muff Hat Combines Warmth and Convenience in One Winter Accessory
- Danholm Collection Announces Sale of 16689 Broadwater Ave in Winter Garden, Highlighting Strong Performance in Twinwaters Community
- New Repositionable Handheld Easel Offers Artists Greater Freedom and Flexibility
- Strong Clinical Results for Breakthrough Liver Diagnostic Platform; ENDRA Life Sciences (N A S D A Q: NDRA) $NDRA
- 46th International Symposium On Forecasting – Dates, Venue And Speakers Announced
- Phoenix Rebellion Therapy Celebrates 10 Years Helping Utahns Overcome Trauma as Utah Faces Nation's 2nd-Highest Rate of Mental Health Challenges
- Greater Englewood Chamber of Commerce to Host Member Meeting on March 11, 2026